ID   526-mel
AC   CVCL_8051
SY   526-MEL; 526 mel; 526mel; 526MEL; 526; MEL-526; Mel526; MEL526
DR   cancercelllines; CVCL_8051
DR   CGH-DB; 9297-4
DR   Cosmic; 905211
DR   Cosmic; 1303043
DR   GEO; GSM206440
DR   GEO; GSM218052
DR   Progenetix; CVCL_8051
DR   Wikidata; Q54603719
RX   PubMed=8027550;
RX   PubMed=8081556;
RX   PubMed=8537970;
RX   PubMed=9598804;
RX   PubMed=9670966;
RX   PubMed=10048982;
RX   PubMed=15467732;
RX   PubMed=18172304;
RX   PubMed=21857157;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*02:01,03; B*50,62; C*03 (PubMed=9670966).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=9598804).
CC   Omics: Proteomics; 2DE-MS.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Misspelling: 527MEL; GEO=GSM206440.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): Technion Genomics Center
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D10S1248: 15
ST   D12S391: 17,20
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 16,17
ST   D19S433: 14
ST   D1S1656: 17.3,18.3
ST   D21S11: 29,31.2
ST   D22S1045: 11,16
ST   D2S1338: 19,24
ST   D2S441: 11,14
ST   D3S1358: 15,19
ST   D5S818: 11,13
ST   D7S820: 9,12
ST   D8S1179: 14
ST   FGA: 22
ST   Penta D: 9,12
ST   Penta E: 16,18
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 15,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 27
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=8081556; DOI=10.1097/00002371-199407000-00002; PMCID=PMC2561308;
RA   Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A.,
RA   O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J.,
RA   Rosenberg S.A.;
RT   "Locus-specific analysis of human leukocyte antigen class I expression
RT   in melanoma cell lines.";
RL   J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994).
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100; PMCID=PMC2248456;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M.C., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939;
RA   Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F.,
RA   Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.;
RT   "Conservation of genetic alterations in recurrent melanoma supports
RT   the melanoma stem cell hypothesis.";
RL   Cancer Res. 68:122-131(2008).
//
RX   PubMed=21857157; DOI=10.4161/cc.10.17.17068; PMCID=PMC5479465;
RA   Caputo E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
//